Glucagon-Like Peptide-1 Gene Therapy

被引：13

作者：

Rowzee, Anne M. ^{[1
]}

Cawley, Niamh X. ^{[2
]}

Chiorini, John A. ^{[1
]}

Di Pasquale, Giovanni ^{[1
]}

机构：

[1] Natl Inst Dent & Craniofacial Res, Mol Physiol & Therapeut Branch, Bethesda, MD 20892 USA

[2] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cellular Neurobiol Sect, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA

来源：

EXPERIMENTAL DIABETES RESEARCH | 2011年

关键词：

BETA-CELL PROLIFERATION; IN-VIVO EXPRESSION; INSULIN SENSITIVITY; MOUSE MODEL; PROGLUCAGON; PANCREAS; MICE; SECRETION; GLUCOSE; GLP-1;

D O I：

10.1155/2011/601047

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucagon-like peptide 1 (GLP-1) is a small peptide component of the prohormone, proglucagon, that is produced in the gut. Exendin-4, a GLP-1 receptor agonist originally isolated from the saliva of H. suspectum or Gila monster, is a peptide that shares sequence and functional homology with GLP-1. Both peptides have been demonstrated to stimulate insulin secretion, inhibit glucagon secretion, promote satiety and slow gastric emptying. As such, GLP-1 and Exendin-4 have become attractive pharmaceutical targets as an adjunctive therapy for individuals with type II diabetes mellitus, with several products currently available clinically. Herein we summarize the cell biology leading to GLP-1 production and secretion from intestinal L-cells and the endocrine functions of this peptide and Exendin-4 in humans. Additionally, gene therapeutic applications of GLP-1 and Exendin-4 are discussed with a focus on recent work using the salivary gland as a gene therapy target organ for the treatment of diabetes mellitus.

引用

页数：5

共 55 条

[1] Human Parathyroid Hormone Is Secreted Primarily into the Bloodstream After Rat Parotid Gland Gene Transfer [J].

Adriaansen, J. ;

Perez, P. ;

Zheng, C. ;

Collins, M. T. ;

Baum, B. J. .

HUMAN GENE THERAPY, 2011, 22 (01) :84-92

[2] Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells [J].

Anini, Y ;

Brubaker, PL .

ENDOCRINOLOGY, 2003, 144 (07) :3244-3250

[3]

Baum BJ, 2010, METHODS MOL BIOL, V666, P3, DOI 10.1007/978-1-60761-820-1_1

[4] Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1 [J].

Brubaker, Patricia L. .

ENDOCRINOLOGY, 2010, 151 (05) :1984-1989

[5] Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2 [J].

Brubaker, PL ;

Anini, Y .

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2003, 81 (11) :1005-1012

[6] GLP-1 receptor signaling:: effects on pancreatic β-cell proliferation and survival [J].

Buteau, J. .

DIABETES & METABOLISM, 2008, 34 :S73-S77

[7] The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose [J].

Chang, AM ;

Jakobsen, G ;

Sturis, J ;

Smith, MJ ;

Bloem, CJ ;

An, B ;

Galecki, A ;

Halter, JB .

DIABETES, 2003, 52 (07) :1786-1791

[8] Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes [J].

Choi, S ;

Oh, S ;

Lee, M ;

Kim, SW .

MOLECULAR THERAPY, 2005, 12 (05) :885-891

[9]

Cotrim Ana P, 2006, Dent Clin North Am, V50, P157, DOI 10.1016/j.cden.2005.11.002

[10] GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE SECRETION IN RESPONSE TO NUTRIENT INGESTION IN MAN - ACUTE POSTPRANDIAL AND 24-H SECRETION PATTERNS [J].

ELLIOTT, RM ;

MORGAN, LM ;

TREDGER, JA ;

DEACON, S ;

WRIGHT, J ;

MARKS, V .

JOURNAL OF ENDOCRINOLOGY, 1993, 138 (01) :159-166

← 1 2 3 4 5 6 →